Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

X4 Pharmaceuticals (XFOR) Operating Expenses (2018 - 2025)

Historic Operating Expenses for X4 Pharmaceuticals (XFOR) over the last 8 years, with Q3 2025 value amounting to -$11.9 million.

  • X4 Pharmaceuticals' Operating Expenses rose 2486.31% to -$11.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.7 million, marking a year-over-year decrease of 10339.0%. This contributed to the annual value of $39.0 million for FY2024, which is 6376.74% down from last year.
  • Per X4 Pharmaceuticals' latest filing, its Operating Expenses stood at -$11.9 million for Q3 2025, which was up 2486.31% from -$9.9 million recorded in Q2 2025.
  • In the past 5 years, X4 Pharmaceuticals' Operating Expenses registered a high of $91.5 million during Q2 2024, and its lowest value of -$19.7 million during Q1 2025.
  • Moreover, its 5-year median value for Operating Expenses was $21.3 million (2022), whereas its average is $20.4 million.
  • Within the past 5 years, the most significant YoY rise in X4 Pharmaceuticals' Operating Expenses was 25440.42% (2024), while the steepest drop was 15837.8% (2024).
  • Over the past 5 years, X4 Pharmaceuticals' Operating Expenses (Quarter) stood at $29.1 million in 2021, then dropped by 11.97% to $25.6 million in 2022, then dropped by 1.48% to $25.2 million in 2023, then soared by 46.22% to $36.8 million in 2024, then plummeted by 132.4% to -$11.9 million in 2025.
  • Its Operating Expenses stands at -$11.9 million for Q3 2025, versus -$9.9 million for Q2 2025 and -$19.7 million for Q1 2025.